14 selected medicines in centralized procurement will be investigated!

Recently, the centralized procurement network for medicines and medical consumables in Liaoning Province issued a notice on the investigation of drug prices and supply of abnormal drugs in November 2021, and 14 drugs were named
.
According to the "Notice", from November 1-30, 2021, medical institutions and monitoring points in Liaoning Province reported 64 pieces of information about drug prices and supply abnormalities
.
After screening and verification, 14 drugs need further investigation
.
According to the analysis, the 14 drugs that need to be transferred this time are all injections, involving Sinopharm Shenyang, Shenyang Haotian Pharmaceutical, Liaoning New Special Medicine, China Resources Liaoning Pharmaceutical, Sinopharm Dandong, Liaoning Pharmaceutical Foreign Trade, Liaoning Winbond 10 pharmaceutical companies including Sinopharm, Shanghai Pharmaceutical Kangdele (Liaoning), and Sinopharm Group Jinzhou
.
In fact, since the launch of volume procurement, there have been many incidents in which selected products have been investigated due to factors such as production and price
.
In this regard, the industry believes that this is caused by the country's stricter control over centralized procurement of drugs
.
Regarding the supply guarantee for the products selected in the national centralized procurement, the General Office of the State Council issued a clear requirement in the "National Organization of Drug Centralized Procurement and Use Pilot Program" issued on January 17, 2019, to establish an investigation on the product quality and supply capacity of the shortlisted companies.
, Evaluation, assessment, and monitoring system
.
Subsequently, the National Medical Insurance Administration issued the "Guiding Opinions of the National Medical Insurance Administration on Establishing a Medical Price and Recruitment Credit Evaluation System" in August 2020, and also clearly proposed the establishment of a credit evaluation catalogue list to prevent improper price behaviors and disrupt the order of centralized procurement.
, Malicious breach of contract, and other behaviors that violate the city's credit, shall be included in the evaluation of medical prices and recruitment credit
.
Correspondingly, companies will also face penalties for their products being removed from the Internet
.
Therefore, in the context of increasingly strict supervision, in recent years, it has been often seen that pharmaceutical companies in various regions have been announced and punished due to refusal to supply and abnormal prices after selection in centralized procurement
.
For example, on April 14, 2021, the Zhejiang Pharmaceutical Equipment Procurement Center issued a "Notice on the results of the procurement of cefmetazole injection dosage forms"
.
The "Notice" shows that after the results of the planned selection of the first batch of drugs in Zhejiang Province for centralized procurement of drugs were announced and formally implemented, a certain pharmaceutical company declared the selected "Cefmetazole Sodium for Injection" (powder injection, specification 1.
0g), Because the company refuses to fulfill its obligation to be selected, and fails to complete the work of signing a purchase and sales agreement and establishing a distribution relationship, it will be treated as a non-selected product
.
At the same time, the notice also pointed out that all medical and health institutions can protect their rights in accordance with the law if they cause losses or other civil rights are violated because the company fails to perform its obligations as required
.
In addition, on June 4, 2020, the website of the Yunnan Provincial Medical Insurance Bureau also issued the "Letter on Submitting Written Statements and Production Capacity Lists", involving a total of 14 countries' centralized procurement of selected drugs
.
Among them, the document mentioned that in the process of monitoring the national centralized procurement of drugs, the Yunnan Provincial Medical Insurance Bureau found that some selected companies failed to supply the selected drugs in time and in accordance with the needs of medical institutions.
According to policy regulations, relevant drug manufacturers need to submit submissions.
The written description of the supply and the production capacity list
.
If it is verified that there is no reasonable reason, the supply status will be included in the Yunnan Provincial Medical Insurance Credit Supervision Record and submitted to the National Joint Procurement Office in accordance with relevant regulations, and relevant drugs will be substituted as required to ensure the supply of drugs to medical institutions
.
The industry believes that, from the above point of view, if these 14 pharmaceutical companies in Liaoning Province fail to submit the "Description of Drug Prices and Supply Abnormalities" by 17:00 on December 10, the products may be withdrawn from the Internet
.
In general, under the national key monitoring system, in addition to price competition, the future centralized procurement of varieties will also face the PK of quality and production capacity.
Only when these three aspects are done well, can they continue to expand.
More opportunities are ushered in centralized procurement
.